Heart failure-related quality-of-life impairment after myocardial infarction

Wohlfahrt, Peter; Jenča, Dominik; Stehlik, Josef; Melenovský, Vojtěch; Mrázková, Jolana; Staněk, Vladimír; Kettner, Jiří; Šramko, Marek; Želı́zko, Michael; Adámková, Věra; Piťha, Jan; Kautzner, Josef

doi:10.1007/s00392-022-02008-z

Cited by 8 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HF‐related quality‐of‐life impairment is common in patients after MI. 21 In the present study, KCCQ scores <50 were present in ≈13% of patients 30 days after their MI. Interestingly, 66% of these patients were Killip class I during the hospital stay, suggesting that a large proportion of patients either developed HF symptoms after hospital discharge, or that the Killip class is insufficiently sensitive to HF symptoms.…”

Section: Discussionsupporting

confidence: 47%

Remote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death

Wohlfahrt,

Jenča,

Melenovský

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

Background Heart failure is a common complication after myocardial infarction (MI) and is associated with increased mortality. Whether remote heart failure symptoms assessment after MI can improve risk stratification is unknown. The authors evaluated the association of the 23‐item Kansas City Cardiomyopathy Questionnaire (KCCQ) with all‐cause mortality after MI. Methods and Results Prospectively collected data from consecutive patients hospitalized for MI at a large tertiary heart center between June 2017 and September 2022 were used. Patients remotely completed the KCCQ 1 month after discharge. A total of 1135 (aged 64±12 years, 26.7% women) of 1721 eligible patients completed the KCCQ. Ranges of KCCQ scores revealed that 30 (2.6%), 114 (10.0%), 274 (24.1%), and 717 (63.2%) had scores <25, 25 to 49, 50 to 74, and ≥75, respectively. During a mean follow‐up of 46 months (interquartile range, 29–61), 146 (12.9%) died. In a fully adjusted analysis, KCCQ scores <50 were independently associated with mortality (hazard ratio [HR], 6.05 for KCCQ <25, HR, 2.66 for KCCQ 25–49 versus KCCQ ≥50; both P <0.001). Adding the 30‐day KCCQ to clinical risk factors improved risk stratification: change in area under the curve of 2.6 (95% CI, 0.3–5.0), Brier score of −0.6 (95% CI, −1.0 to −0.2), and net reclassification improvement of 0.71 (95% CI, 0.45–1.04). KCCQ items most strongly associated with mortality were walking impairment, leg swelling, and change in symptoms. Conclusions Remote evaluation of heart failure symptoms using the KCCQ among patients recently discharged for MI identifies patients at risk for mortality. Whether closer follow‐up and targeted therapy can reduce mortality in high‐risk patients warrants further study.

show abstract

Section: Discussionsupporting

confidence: 47%

Remote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death

Wohlfahrt,

Jenča,

Melenovský

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…As the infarct size expands and non-infarcted areas remodel, the risk of developing heart failure or death remains high ( 51 , 52 ). A questionnaire survey involving 850 patients showed that 2 out of every 5 patients had heart failure-related quality of life impairment after MI, causing a significant social and economic burden ( 53 ).…”

Section: Discussionmentioning

confidence: 99%

A bibliometric analysis of myocardial ischemia/reperfusion injury from 2000 to 2023

Wang

Guo

Zhang

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundMyocardial ischemia/reperfusion injury (MIRI) refers to the more severe damage that occurs in the previously ischemic myocardium after a short-term interruption of myocardial blood supply followed by restoration of blood flow within a certain period of time. MIRI has become a major challenge affecting the therapeutic efficacy of cardiovascular surgery.MethodsA scientific literature search on MIRI-related papers published from 2000 to 2023 in the Web of Science Core Collection database was conducted. VOSviewer was used for bibliometric analysis to understand the scientific development and research hotspots in this field.ResultsA total of 5,595 papers from 81 countries/regions, 3,840 research institutions, and 26,202 authors were included. China published the most papers, but the United States had the most significant influence. Harvard University was the leading research institution, and influential authors included Lefer David J., Hausenloy Derek J., Yellon Derek M., and others. All keywords can be divided into four different directions: risk factors, poor prognosis, mechanisms and cardioprotection.ConclusionResearch on MIRI is flourishing. It is necessary to conduct an in-depth investigation of the interaction between different mechanisms and multi-target therapy will be the focus and hotspot of MIRI research in the future.

show abstract

“…At present, more and more studies have taken the KCCQ as a key evaluation index in the treatment of patients with HF. For example, Wohlfahrt et al (2022) report HF-related quality-of-life impairment after myocardial infarction. DeVore et al (2022) report the association of improvement in the left ventricular ejection fraction with outcomes in patients with HF with a reduced ejection fraction: data from CHAMP-HF.…”

Section: Discussionmentioning

confidence: 99%

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients

Wang

Zhang²,

Zhu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

The aim of the present study is to investigate the quantitative effects of sodium–glucose cotransporter-2 (SGLT-2) inhibitors on the quality of life in heart failure (HF) patients. A total of 14,674 HF patients from two dapagliflozin and three empagliflozin studies is included for analysis via the nonlinear mixed-effect modeling (NONMEM) software, among which the change rate of the Kansas City Cardiomyopathy Questionnaire (KCCQ) score is used as the evaluation index. There is no significant difference in the pharmacodynamics influencing the quality of life in HF patients between the SGLT-2 inhibitors: 10 mg/day dapagliflozin and 10 mg/day empagliflozin. For the clinical summary score (CSS), total symptom score (TSS), and overall summary score (OSS), the Emax of the SGLT-2 inhibitors on the quality of life in HF patients is 3.74%, 4.43%, and 4.84%, respectively, and ET50 is 2.23, 4.37, and 7.15 weeks, respectively. In addition, the time duration of achieving 25%, 50%, 75%, and 80% Emax is 0.75, 2.23, 6.69, and 8.92 weeks for the CSS; 1.46, 4.37, 13.11, and 17.48 weeks for the TSS; and 2.39, 7.15, 21.45, and 28.6 weeks for the OSS, respectively. Therefore, to reach the plateau period (80% of Emax) of SGLT-2 inhibitors on the CSS, TSS, and OSS, 10 mg/day dapagliflozin (or 10 mg/day empagliflozin) is required to be taken for 8.92 weeks, 17.48 weeks, and 28.6 weeks, respectively. This is the first time that the quantitative effects of SGLT-2 inhibitors on the quality of life in HF patients are being explored.

show abstract

Heart failure-related quality-of-life impairment after myocardial infarction

Cited by 8 publications

References 34 publications

Remote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death

Remote Heart Failure Symptoms Assessment After Myocardial Infarction Identifies Patients at Risk for Death

A bibliometric analysis of myocardial ischemia/reperfusion injury from 2000 to 2023

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients

Contact Info

Product

Resources

About